Browsing Tag
Boston
63 posts
Eastern Bankshares (EBC) posts record operating income of $106.5m, lifts wealth assets to $11.5bn
Eastern Bankshares posts record $106.5M operating income and a 5% buyback authorization, but CRE payoffs and rising deposit costs test the growth thesis.
Rhythm Pharmaceuticals (RYTM) TRANSCEND trial in NEJM shows 19.8% placebo-adjusted BMI reduction
Rhythm Pharma (RYTM) TRANSCEND Phase 3 published in NEJM validates IMCIVREE for acquired hypothalamic obesity. 10,000-patient US market launch trajectory ahead.
US heat wave puts 185 million under alerts as July 4 events are cancelled
A dangerous US heat wave has put 185 million people under alerts, cancelled July 4 events and strained power grids across major cities.
Could elsunersen become the asset that steadies Praxis Precision Medicines’ CNS pipeline?
Find out how Praxis’ FDA Breakthrough Therapy Designation for elsunersen could affect PRAX stock, rare epilepsy strategy and precision neuroscience today!
Why Trump’s proof-of-citizenship voting order just hit a major court wall
Trump’s proof-of-citizenship voting order faces a major court setback as judges, states and Congress clash over election authority.
US court dismisses Trump administration challenge to Los Angeles sanctuary-city policy
Los Angeles kept control of its city resources, but the Trump administration can amend its case. The sanctuary-city fight remains far from settled in court.
FIFA World Cup 2026 host cities explained: How US, Canada and Mexico will stage 104 matches
World Cup 2026 is a city operations test. Sixteen host markets must move fans, manage crowds and turn football into tourism value.
Tango Therapeutics (NASDAQ: TNGX) jumps 11% into May 11 earnings and pivotal pancreatic cancer data
Tango Therapeutics is up 22-fold from $1.04 in twelve months. The May 11 earnings print decides whether vopimetostat justifies the run or breaks it.
Seaport Therapeutics seeks $212m IPO as neuropsychiatry biotech window reopens
Seaport’s IPO tests biotech appetite before key depression data. Here’s why SPTX, PureTech, and psychiatry investors are watching.
Mauna Kea Technologies FY2025 results show why ALMKT is no longer just a restructuring story
Mauna Kea Technologies says FY2025 reset its balance sheet and reignited growth. Read what the debt cut, U.S. sales surge, and 2026 outlook mean.